VHL and cancer: To expand our study to additional ccRCC models, we took a systematic approach and identified VHL mutant ccRCC cell models which have a non-synonymous and predicted damaging or TCGA/COSMIC hotspot SMARCB1 (n = 3) or ARID1A (n = 1) mutation from the cell line encyclopedia (CCLE)23 and compared their PAX8 inhibition sensitivity to their SMARCB1/ARID1A wild-type (WT) counterparts (n = 13) using loss-of-function data from the cancer dependency map project (DepMap).24